Literature DB >> 23649377

Small intestinal bacterial overgrowth and orocecal transit time in patients of inflammatory bowel disease.

S V Rana1, S Sharma, A Malik, J Kaur, K K Prasad, S K Sinha, K Singh.   

Abstract

BACKGROUND: Inflammatory bowel disease (IBD) consists of Ulcerative colitis (UC) and Crohn's disease (CD). These two conditions share many common features-diarrhea, bloody stools, weight loss, abdominal pain, fever and fatigue. Small intestinal bacterial overgrowth (SIBO) is frequent in patients with CD but it has not been studied in UC Indian patients. AIM: The study was planned to measure orocecal transit time (OCTT) and SIBO in UC and CD patients.
METHODS: One hundred thirty-seven patients of IBD (95 UC and 42 CD) and 115 healthy controls were enrolled. OCTT and SIBO were measured by lactulose and glucose hydrogen breath test respectively. Concentration of hydrogen and methane were measured by SC microlyser from Quintron, USA.
RESULTS: Mean±standard deviation (SD) of OCTT in patients of IBD was significantly higher as compared to controls. Furthermore, OCTT was significantly higher in CD patients as compared to UC patients. It was also observed that occurrence of SIBO was significantly higher in IBD patients as compared to controls. The occurrence of SIBO in CD (45.2%) was significantly higher as compared to patients in UC (17.8%) group. Percentage of methane positive IBD patients (2.9%) was significantly lower as compared to methane positive controls (24.4%).
CONCLUSION: OCTT was significantly delayed in IBD patients as compared to controls and in CD patients as compared to UC patients. OCTT was significantly higher in SIBO positive IBD patients as compared to SIBO negative patients. Thus, we can suggest that delayed OCTT would have been the cause of increased SIBO in these patients.

Entities:  

Mesh:

Year:  2013        PMID: 23649377     DOI: 10.1007/s10620-013-2694-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

1.  Glucose malabsorption associated with rapid intestinal transit.

Authors:  J H Sellin; R Hart
Journal:  Am J Gastroenterol       Date:  1992-05       Impact factor: 10.864

2.  Medical therapy for Crohn's disease.

Authors:  S B Hanauer
Journal:  Curr Opin Gastroenterol       Date:  1999-07       Impact factor: 3.287

Review 3.  Inflammatory bowel disease approaching the 3rd millennium: pathogenesis and therapeutic implications?

Authors:  S Ardizzone; S Bollani; G Manzionna; G Bianchi Porro
Journal:  Eur J Gastroenterol Hepatol       Date:  1999-01       Impact factor: 2.566

4.  Orocecal transit time and bacterial overgrowth in patients with Crohn's disease.

Authors:  F Castiglione; G Del Vecchio Blanco; A Rispo; G Petrelli; G Amalfi; A Cozzolino; I Cuccaro; G Mazzacca
Journal:  J Clin Gastroenterol       Date:  2000-07       Impact factor: 3.062

Review 5.  Biologic therapy for inflammatory bowel disease.

Authors:  Sandro Ardizzone; Gabriele Bianchi Porro
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 6.  Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease.

Authors:  R B Sartor
Journal:  Gastroenterol Clin North Am       Date:  1995-09       Impact factor: 3.806

7.  Methane production during lactulose breath test is associated with gastrointestinal disease presentation.

Authors:  Mark Pimentel; Andrew G Mayer; Sandy Park; Evelyn J Chow; Aliya Hasan; Yuthana Kong
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

8.  Orocecal transit time in patients in the chronic phase of corrosive injury.

Authors:  S V Rana; R Kochhar; R Pal; B Nagi; K Singh
Journal:  Dig Dis Sci       Date:  2007-12-20       Impact factor: 3.199

9.  Use of pulmonary hydrogen (H 2 ) measurements to quantitate carbohydrate absorption. Study of partially gastrectomized patients.

Authors:  J H Bond; M D Levitt
Journal:  J Clin Invest       Date:  1972-05       Impact factor: 14.808

10.  How to interpret hydrogen breath tests.

Authors:  Uday C Ghoshal
Journal:  J Neurogastroenterol Motil       Date:  2011-07-14       Impact factor: 4.924

View more
  30 in total

1.  Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease.

Authors:  Rajkumar Malayandi; Phani Krishna Kondamudi; P K Ruby; Deepika Aggarwal
Journal:  Drug Deliv Transl Res       Date:  2014-04       Impact factor: 4.617

2.  Nanoparticulate Drug Delivery Systems Targeting Inflammation for Treatment of Inflammatory Bowel Disease.

Authors:  Sufeng Zhang; Robert Langer; Giovanni Traverso
Journal:  Nano Today       Date:  2017-10-09       Impact factor: 20.722

3.  Response to Paterson et al.

Authors:  Ali Rezaie; Michelle Buresi; Satish Rao
Journal:  Am J Gastroenterol       Date:  2017-12       Impact factor: 10.864

Review 4.  Gastroduodenal "Dysbiosis": a New Clinical Entity.

Authors:  Ayesha Shah; Mark Morrison; Gerald J Holtmann
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

5.  Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease.

Authors:  Madelyn C Houser; Jianjun Chang; Stewart A Factor; Eric S Molho; Cyrus P Zabetian; Erin M Hill-Burns; Haydeh Payami; Vicki S Hertzberg; Malú G Tansey
Journal:  Mov Disord       Date:  2018-03-23       Impact factor: 10.338

Review 6.  Colon-targeted oral drug delivery systems: design trends and approaches.

Authors:  Seth Amidon; Jack E Brown; Vivek S Dave
Journal:  AAPS PharmSciTech       Date:  2015-06-13       Impact factor: 3.246

7.  Fungal Signature in the Gut Microbiota of Pediatric Patients With Inflammatory Bowel Disease.

Authors:  Christel Chehoud; Lindsey G Albenberg; Colleen Judge; Christian Hoffmann; Stephanie Grunberg; Kyle Bittinger; Robert N Baldassano; James D Lewis; Frederic D Bushman; Gary D Wu
Journal:  Inflamm Bowel Dis       Date:  2015-08       Impact factor: 5.325

8.  Small intestinal bacterial overgrowth in patients with inflammatory bowel disease: A case-control study.

Authors:  Uday C Ghoshal; Ankur Yadav; Bushra Fatima; Anand Prakash Agrahari; Asha Misra
Journal:  Indian J Gastroenterol       Date:  2021-08-14

9.  Testing and Treating Small Intestinal Bacterial Overgrowth Reduces Symptoms in Patients with Inflammatory Bowel Disease.

Authors:  Shirley Cohen-Mekelburg; Zaid Tafesh; Elliot Coburn; Russell Weg; Neena Malik; Colleen Webb; Hoda Hammad; Ellen Scherl; Brian P Bosworth
Journal:  Dig Dis Sci       Date:  2018-05-14       Impact factor: 3.199

Review 10.  Ulcerative colitis as a polymicrobial infection characterized by sustained broken mucus barrier.

Authors:  Shui-Jiao Chen; Xiao-Wei Liu; Jian-Ping Liu; Xi-Yan Yang; Fang-Gen Lu
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.